Senator Charles E. Grassley (R-IA) has previously criticized the NIH’s
enforcement of financial conflicts of interest. A 2008 report by the HHS Office
of the Inspector General stated that the NIH lacked oversight of conflict of
interests at grant-receiving institutions. …
“It is outrageous that doctors who are testing and, in many cases, recommending
the use of certain high-risk medical devices are being compensated with stock in
the very companies that make the devices. …
While the Florence expansion project began in 2007 well before cases of H1N1
“swine flu” began emerging, the additional Tamiflu capacity it provides
fits well with Roche’s efforts to ramp-up manufacture. …
Aspen will distribute Glaxo’s meds in South Africa, and the two companies will
work together to sell their products across the remainder of the continent. …
Ironically, bio-opportunism reflects one of the biotech industry’s best
qualities: your competition does not have to fail for you to succeed. In fact,
your competitors’ successes can often validate your approach, in which case a
little coattail riding can be warranted. …
UM is one of a number of universities to get deeply involved in drug development
work. The state’s universities and colleges are among the nation’s most prolific
when it comes to patenting new biotech IP. …
When rumors recently began circulating that a union drive might be brewing in
San Francisco, the response from the company was immediate–including mandatory
“Morale Meetings” to dissuade employees. But company leaders failed to address
workers’ complaints that they have gone without any pay raises, sometimes for
more than two years, because Team Leaders have neglected to hold “Job Dialogue”
meetings (known as “annual performance reviews” in traditional
corporate-speak).
…
A serious financial crisis is inevitable when you live too far above your means
for too long. This applies whether you’re talking about a single-family
household or an entire country. As this article points out, countries in crisis
need to learn to live within their means – just like you and I. This may mean
increasing exports and cutting imports. …
Some trials have shown that having this info on genetic variation can help docs
pinpoint the proper warfarin dosage. And that’s important, because even small
changes in dosage can have big effects, either on the not-enough-thinning side
or the so-much-thinning-it’s dangerous side. …
The international drama playing out right now before our eyes is an example of
how citizens around the world can be easily manipulated by doctors and
politicians engaging in fear mongering in the name of disease control to forward
agendas that have more to do with ideology, power and corporate profits than
health. …